Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer, Cancer, Cancer, Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/8/2017 |
| Start Date: | June 2009 |
| End Date: | July 2015 |
A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat
given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer
(NSCLCA) brain metastases in patient with 1-4 lesions.
given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer
(NSCLCA) brain metastases in patient with 1-4 lesions.
Inclusion Criteria:
- All patients age 18 years and older with histologically proven non-small cell lung
cancer and 1-4 brain metastases, each measuring less than 2 cm will be eligible. Prior
surgery or radiation is allowed as long as the target metastatic lesion(s) has not
been treated with previous radiation.
- Adequate organ function (section 3.1.10).
- ECOG performance status 0-2.
- Life expectancy of >=12 weeks.
- Systemic chemotherapy washout period >=7 days.
Exclusion Criteria:
Patients who have previously been treated with whole brain irradiation, pediatric patients
(age <18), pregnant women, and patients who are unable to give informed consent.
We found this trial at
2
sites
Click here to add this to my saved trials
Stanford University School of Medicine Vast in both its physical scale and its impact on...
Click here to add this to my saved trials